December 6, 2021 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced that “embecta” will be the name of the independent, publicly-traded company that will hold BD’s Diabetes Care business upon the completion of the previously announced spinoff, which is expected to close in the second quarter of calendar year 2022.
Devdatt (Dev) Kurdikar, worldwide president of BD Diabetes Care, who will become CEO of embecta upon completion of the spinoff said, “The Diabetes Care business is the trusted partner our customers and people living with diabetes have known for nearly a century, now with a single focus and the financial flexibility to pursue organic and inorganic innovations that will give more people a better life. We have assembled a diverse and experienced leadership team that is excited about the possibilities ahead, and our global team is passionate about the profound impact they can have on the growing number of people who live with this chronic and prevalent disease. Together, we look forward to making embecta synonymous with a life unlimited by diabetes.”
In addition to Kurdikar, after completion of the spinoff, embecta will be led by:
- Ginny Blocki, senior vice president, product management and global marketing
- Tom Blount, senior vice president and president, North America.
- Shaun Curtis, senior vice president, global manufacturing and supply chain
- Jake Elguicze, senior vice president and chief financial officer
- Ajay Kumar, senior vice president and chief human resources officer.
- Jeff Mann, senior vice president, general counsel and head of corporate development.
- Slobodan Radumilo, senior vice president and president, international.
- Colleen Riley, senior vice president and chief technology officer